Drugs / rgp120/HIV-1MN
last change Mar 1993 re-read 2 minutes ago

rgp120/HIV-1MN

Vaccine

Developed for
HIV infectious disease
Investigated by
Genentech, Inc. · Glaxo Wellcome · National Institute of Allergy and Infectious Diseases (NIAID)

Trials 1 · a red edge is where a trial was stopped

19931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00000755 ? → Mar 1993 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as rgp120/HIV-1MN ClinicalTrials.gov intervention name — accepted as the source's own label NCT00000755
Modality Vaccine “rgp120/HIV-1MN vaccineNCT00000755